美国NDC复合药物数据库文件

药品名称：商品名称：药品NDC：报告期内： -格式:2020-5-3
NDC包装id：市场分类：活性成分：持证企业：

美国NDC复合药物数据库文件4843条(本栏目更新到2026-3-31)

药品名称(分析)

商品名

药品NDC

专利人(分析)

报告期内

活性成分

市场分类

规格(分析)

NDC包装id

121022 HYDROCORTISONE 2.5% / IODOQUINOL 1% / KETOCONAZOLE 2%

HUMAN COMPOUNDED DRUG

72934-2370

SKNV

2024-1

KETOCONAZOLE; HYDROCORTISONE; IODOQUINOL

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

2 g/100 mL; 2.5 g/100 mL; 1 g/100 mL

72934-2370-2

Induction 4 to1 High K (50 mEq) In Plasmalyte A, ph 7.4 with Tromethamine 500ml Bag

HUMAN COMPOUNDED DRUG

71285-0111

Central Admixture Pharmacy Services, Inc.

2024-1

MANNITOL; MAGNESIUM SULFATE HEPTAHYDRATE; SODIUM CHLORIDE; POTASSIUM CHLORIDE; MAGNESIUM CHLORIDE; TROMETHAMINE; DEXTROSE MONOHYDRATE; SODIUM ACETATE; SODIUM GLUCONATE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

3.6 g/500 mL; 20.3 meq/500 mL; 1.9725 g/500 mL; 3.86375 g/500 mL; .1125 g/500 mL; 2.268 g/500 mL; 6.51 g/500 mL; 1.38 g/500 mL; 1.8825 g/500 mL

71285-0111-1

Vancomycin 1.75gm added to NS

HUMAN COMPOUNDED DRUG

71285-7060

Central Admixture Pharmacy Services, Inc.

2024-1

VANCOMYCIN HYDROCHLORIDE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

1.75 g/500 mL

71285-7060-1

Potassium Phosphate 30mmol added to NS

HUMAN COMPOUNDED DRUG

71285-7016

Central Admixture Pharmacy Services, Inc.

2024-1

POTASSIUM PHOSPHATE, DIBASIC

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

30 mmol/500 mL

71285-7016-1

Oxytocin 30units added to LR

HUMAN COMPOUNDED DRUG

71285-6039

Central Admixture Pharmacy Services, Inc.

2024-1

OXYTOCIN

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

30 [USP'U]/500 mL

71285-6039-1

Trophamine 3% / Dextrose 5% With Calcium Gluconate 3.75mEq and Heparin 125 units 250ml in 250ml bag

HUMAN COMPOUNDED DRUG

72196-0419

Central Admixture Pharmacy Services, Inc.

2024-1

GLUTAMIC ACID; LYSINE ACETATE; SERINE; TYROSINE; N-ACETYLTYROSINE; THREONINE; CYSTEINE HYDROCHLORIDE; HISTIDINE; ARGININE; TAURINE; DEXTROSE MONOHYDRATE; LEUCINE; METHIONINE; PROLINE; ASPARTIC ACID; ISOLEUCINE; ALANINE; GLYCINE; PHENYLALANINE; TRYPTOPHAN; VALINE; CALCIUM GLUCONATE MONOHYDRATE; HEPARIN SODIUM

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

.375 g/250 mL; .9 g/250 mL; .285 g/250 mL; .033 g/250 mL; .18 g/250 mL; .315 g/250 mL; .018 g/250 mL; .36 g/250 mL; .9 g/250 mL; .01875 g/250 mL; 12.5 g/250 mL; 1.05 g/250 mL; .255 g/250 mL; .51 g/250 mL; .24 g/250 mL; .615 g/250 mL; .405 g/250 mL; .27 g/250 mL; .36 g/250 mL; .15 g/250 mL; .585 g/250 mL; 3.75 meq/250 mL; 125 U/250 mL

72196-0419-1

Fentanyl Citrate

HUMAN COMPOUNDED DRUG

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

10 ug/1 mL

73177-102-05

Fentanyl Citrate

HUMAN COMPOUNDED DRUG

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

10 ug/1 mL

73177-102-03

Fentanyl Citrate

HUMAN COMPOUNDED DRUG

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

10 ug/1 mL

73177-102-27

Fentanyl Citrate

HUMAN COMPOUNDED DRUG

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

10 ug/1 mL

73177-102-01

Phenylephrine

HUMAN COMPOUNDED DRUG

73177-108

STAQ Pharma Inc

2024-2

PHENYLEPHRINE HYDROCHLORIDE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

100 ug/1 mL

73177-108-03

Ropivacaine

HUMAN COMPOUNDED DRUG

73177-109

STAQ Pharma Inc

2024-2

ROPIVACAINE HYDROCHLORIDE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

2 mg/1 mL

73177-109-20

Ropivacaine

HUMAN COMPOUNDED DRUG

73177-109

STAQ Pharma Inc

2024-2

ROPIVACAINE HYDROCHLORIDE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

2 mg/1 mL

73177-109-13

Ropivacaine

HUMAN COMPOUNDED DRUG

73177-109

STAQ Pharma Inc

2024-2

ROPIVACAINE HYDROCHLORIDE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

2 mg/1 mL

73177-109-26

Ropivacaine

HUMAN COMPOUNDED DRUG

73177-109

STAQ Pharma Inc

2024-2

ROPIVACAINE HYDROCHLORIDE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

2 mg/1 mL

73177-109-14

Morphine Sulfate

HUMAN COMPOUNDED DRUG

71449-022

Denver Solutions, LLC dba Leiters Health

2024-2

MORPHINE SULFATE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

5 mg/1 mL

71449-022-32

Ropivacaine Hydrochloride

HUMAN COMPOUNDED DRUG

71449-070

Denver Solutions, LLC dba Leiters Health

2024-2

ROPIVACAINE HYDROCHLORIDE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

2 mg/1 mL

71449-070-25

Moxifloxacin

HUMAN COMPOUNDED DRUG

71449-097

Denver Solutions, LLC dba Leiters Health

2024-2

MOXIFLOXACIN HYDROCHLORIDE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

5 mg/1 mL

71449-097-42

Bevacizumab

HUMAN COMPOUNDED DRUG

71449-091

Denver Solutions, LLC dba Leiters Health

2024-2

BEVACIZUMAB

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

25 mg/1 mL

71449-091-22

Bevacizumab

HUMAN COMPOUNDED DRUG

71449-091

Denver Solutions, LLC dba Leiters Health

2024-2

BEVACIZUMAB

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

25 mg/1 mL

71449-091-90

网站地图 - 网站开发 - 网站简介 - 会员服务 - 法律声明 - 联系我们 - 药品招商频道 - 药品信息排行 - 2018年版国家基本药物目录 - 意见反馈

浙ICP备16010490号-2 增值电信业务经营许可证：浙B2-20220931　互联网药品信息服务资格证书编号：(浙)-经营性2023-0215　

浙公网安备:330683240604819103159
　医药代理商群１：

医药代理商群２：

医药代理商群３：